Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 1 de 1
Filter
Add more filters











Database
Language
Publication year range
1.
Psychopharmacol Bull ; 52(3): 72-80, 2022 06 27.
Article in English | MEDLINE | ID: mdl-35815178

ABSTRACT

Buprenorphine and naloxone (Suboxone) is a combination medication-assisted treatment (MAT) for opioid use disorder. MAT withdrawal-induced psychosis is a rare clinical presentation. To our best knowledge, only three reports have summarized the characteristic manifestations of buprenorphine withdrawal psychosis, yet all of them were male. In this case report, we present a 41-year-old female patient with bipolar disorder and comorbid substance use disorder who developed new-onset psychosis and relapse of manic symptoms following abrupt discontinuation of Suboxone. Manic and psychotic symptoms remitted after a short-term hospitalization with the treatment of an antipsychotic and a mood stabilizer. In addition to discussing this case presentation and treatment approach, we review existing literature and discuss possible underlying mechanisms to enhance understanding of this clinical phenomenon.


Subject(s)
Antipsychotic Agents , Bipolar Disorder , Buprenorphine , Psychotic Disorders , Substance Withdrawal Syndrome , Adult , Antipsychotic Agents/therapeutic use , Bipolar Disorder/drug therapy , Buprenorphine/adverse effects , Buprenorphine, Naloxone Drug Combination/therapeutic use , Female , Humans , Male , Naloxone/adverse effects , Psychotic Disorders/drug therapy , Substance Withdrawal Syndrome/drug therapy , Substance Withdrawal Syndrome/etiology
SELECTION OF CITATIONS
SEARCH DETAIL